1. Home
  2. UBX vs NEUP Comparison

UBX vs NEUP Comparison

Compare UBX & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UBX
  • NEUP
  • Stock Information
  • Founded
  • UBX 2009
  • NEUP 1996
  • Country
  • UBX United States
  • NEUP United States
  • Employees
  • UBX N/A
  • NEUP N/A
  • Industry
  • UBX Biotechnology: Pharmaceutical Preparations
  • NEUP
  • Sector
  • UBX Health Care
  • NEUP
  • Exchange
  • UBX Nasdaq
  • NEUP Nasdaq
  • Market Cap
  • UBX 13.9M
  • NEUP 12.7M
  • IPO Year
  • UBX 2018
  • NEUP N/A
  • Fundamental
  • Price
  • UBX $0.78
  • NEUP $7.01
  • Analyst Decision
  • UBX Strong Buy
  • NEUP Strong Buy
  • Analyst Count
  • UBX 3
  • NEUP 1
  • Target Price
  • UBX $4.67
  • NEUP $21.00
  • AVG Volume (30 Days)
  • UBX 521.0K
  • NEUP 22.3K
  • Earning Date
  • UBX 08-05-2025
  • NEUP 08-15-2025
  • Dividend Yield
  • UBX N/A
  • NEUP N/A
  • EPS Growth
  • UBX N/A
  • NEUP N/A
  • EPS
  • UBX N/A
  • NEUP 0.00
  • Revenue
  • UBX N/A
  • NEUP $15,662,715.00
  • Revenue This Year
  • UBX N/A
  • NEUP N/A
  • Revenue Next Year
  • UBX N/A
  • NEUP N/A
  • P/E Ratio
  • UBX N/A
  • NEUP $4,149.50
  • Revenue Growth
  • UBX N/A
  • NEUP N/A
  • 52 Week Low
  • UBX $0.66
  • NEUP $2.90
  • 52 Week High
  • UBX $3.10
  • NEUP $126.00
  • Technical
  • Relative Strength Index (RSI)
  • UBX 48.12
  • NEUP N/A
  • Support Level
  • UBX $0.67
  • NEUP N/A
  • Resistance Level
  • UBX $0.83
  • NEUP N/A
  • Average True Range (ATR)
  • UBX 0.09
  • NEUP 0.00
  • MACD
  • UBX 0.01
  • NEUP 0.00
  • Stochastic Oscillator
  • UBX 24.67
  • NEUP 0.00

About UBX Unity Biotechnology Inc.

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.

About NEUP Neuphoria Therapeutics Inc. Common Stock

Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.

Share on Social Networks: